Current Report Filing (8-k)
April 19 2023 - 9:17AM
Edgar (US Regulatory)
0001821586
false
0001821586
2023-04-19
2023-04-19
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): April 19, 2023
MOONLAKE IMMUNOTHERAPEUTICS
(Exact
name of registrant as specified in its charter)
Cayman Islands |
|
001-39630 |
|
98-1711963 |
(State
or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
Dorfstrasse 29
Zug, Switzerland |
|
6300 |
(Address
of principal executive offices) |
|
(Zip
Code) |
41
415108022
(Registrant’s
telephone number, including area code)
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Class A ordinary share, par value $0.0001 per share |
|
MLTX |
|
The
Nasdaq Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
7.01 Regulation FD Disclosure.
On
April 19, 2023, MoonLake Immunotherapeutics (the “Company”) will be posting to its website an investor presentation to be
used in the Company’s April 19, 2023 Capital Markets Day event, including information regarding the Company’s financial position,
near-term catalysts and publication roadmap. A copy of the presentation is included with this Form 8-K for convenience and attached hereto
as Exhibit 99.1. The investor presentation and replays of the webcast will be available on the Company’s website at https://ir.moonlaketx.com.
The
information in this current report on Form 8-K and the exhibit attached hereto shall not be deemed “filed” for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities
of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the
Exchange Act, regardless of any general incorporation language in such filing, unless specifically so incorporated.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
Signature
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
|
MoonLake
Immunotherapeutics |
|
|
Date:
April 19, 2023 |
By: |
/s/
Matthias Bodenstedt |
|
Name: |
Matthias
Bodenstedt |
|
Title: |
Chief
Financial Officer |
2
Helix Acquisition (NASDAQ:HLXA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Helix Acquisition (NASDAQ:HLXA)
Historical Stock Chart
From Jul 2023 to Jul 2024